Ash1l degraders and methods of treatment therewith
US-2024366774-A1 · Nov 7, 2024 · US
Glycoconjugation processes and compositions
US9950054B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9950054-B2 |
| Application number | US-201615347034-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2016 |
| Priority date | Aug 16, 2012 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of preventing, treating or ameliorating a bacterial infection, disease or condition in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic glycoconjugate composition comprising a bacterial capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the polysaccharide is covalently linked to the eTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked to the eTEC spacer through an amide linkage. 2. The method of claim 1 , wherein the bacterial capsular polysaccharide is derived from S. pneumoniae. 3. The method of claim 1 , wherein the infection, disease or condition is associated with S. pneumoniae bacteria. 4. The method of claim 2 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides. 5. The method of claim 1 , wherein the bacterial capsular polysaccharide is derived from N. meningitidis. 6. The method of claim 1 , wherein the infection, disease or condition is associated with N. meningitidis bacteria. 7. The method of claim 5 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Mn-serotype A, C, W135, and capsular polysaccharides. 8. The method of claim 1 , wherein the carrier protein is CRM 197 . 9. A method of inducing a protective immune response in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition comprising a bacterial capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the polysaccharide is covalently linked to the eTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked to the eTEC spacer through an amide linkage. 10. The method of claim 9 , wherein the bacterial capsular polysaccharide is derived from S. pneumoniae. 11. The method of claim 9 , wherein the infection, disease or condition is associated with S. pneumoniae bacteria. 12. The method of claim 10 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides. 13. The method of claim 9 , wherein the bacterial capsular polysaccharide is derived from N. meningitidis. 14. The method of claim 9 , wherein the infection, disease or condition is associated with N. meningitidis bacteria. 15. The method of claim 13 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Mn-serotype A, C, W135, and capsular polysaccharides. 16. The method of claim 9 , wherein the carrier protein is CRM 197 .
Assignees
Inventors
Classifications
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Antibacterial agents · CPC title
Immunostimulants · CPC title
- A61K47/64Primary
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9950054B2 cover?
- The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification A61K47/64. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).